Movement Alert｜Roivant Sciences Rises 8.12% in Pre-Market Trading, Reports Fiscal Q4 Results and Business Updates

Market Focus

May 20

On May 20, Roivant Sciences rose 8.12% in pre-market trading, trading at $30.02/share, with trading volume of approximately $1.71 million.

On the news front, the company reported its fiscal fourth quarter and full-year financial results for the period ended March 31, alongside a comprehensive business progress update. Fiscal Q4 earnings per share from continuing operations came in at $0.28, while quarterly revenue of $2.52 million missed the consensus estimate of $3.82 million. Despite the revenue shortfall, the concurrent disclosure of business developments received a positive market response, driving the stock higher in pre-market trading.

Roivant Sciences is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines in inflammation and immunology. The company operates through its Vant model, building focused subsidiaries across biopharmaceutical businesses and health technology startups. Its pipeline includes VTAMA for psoriasis and atopic dermatitis, batoclimab and IMVT-1402 targeting autoimmune indications, and RVT-3101 for ulcerative colitis and Crohn's disease.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1138905296"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1138905296\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1138905296?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 19:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138905296","market":"us","top_or_hot":-1,"title":"Movement Alert｜Roivant Sciences Rises 8.12% in Pre-Market Trading, Reports Fiscal Q4 Results and Business Updates","media":"Market Focus","content":"<p><p>On May 20, Roivant Sciences rose 8.12% in pre-market trading, trading at $30.02/share, with trading volume of approximately $1.71 million.</p><p>On the news front, the company reported its fiscal fourth quarter and full-year financial results for the period ended March 31, alongside a comprehensive business progress update. Fiscal Q4 earnings per share from continuing operations came in at $0.28, while quarterly revenue of $2.52 million missed the consensus estimate of $3.82 million. Despite the revenue shortfall, the concurrent disclosure of business developments received a positive market response, driving the stock higher in pre-market trading.</p><p>Roivant Sciences is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines in inflammation and immunology. The company operates through its Vant model, building focused subsidiaries across biopharmaceutical businesses and health technology startups. Its pipeline includes VTAMA for psoriasis and atopic dermatitis, batoclimab and IMVT-1402 targeting autoimmune indications, and RVT-3101 for ulcerative colitis and Crohn's disease.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Roivant Sciences Rises 8.12% in Pre-Market Trading, Reports Fiscal Q4 Results and Business Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Roivant Sciences Rises 8.12% in Pre-Market Trading, Reports Fiscal Q4 Results and Business Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-20 19:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 20, Roivant Sciences rose 8.12% in pre-market trading, trading at $30.02/share, with trading volume of approximately $1.71 million.</p><p>On the news front, the company reported its fiscal fourth quarter and full-year financial results for the period ended March 31, alongside a comprehensive business progress update. Fiscal Q4 earnings per share from continuing operations came in at $0.28, while quarterly revenue of $2.52 million missed the consensus estimate of $3.82 million. Despite the revenue shortfall, the concurrent disclosure of business developments received a positive market response, driving the stock higher in pre-market trading.</p><p>Roivant Sciences is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines in inflammation and immunology. The company operates through its Vant model, building focused subsidiaries across biopharmaceutical businesses and health technology startups. Its pipeline includes VTAMA for psoriasis and atopic dermatitis, batoclimab and IMVT-1402 targeting autoimmune indications, and RVT-3101 for ulcerative colitis and Crohn's disease.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROIV","symbol_name":"Roivant Sciences Ltd.","start_time":0,"source_url":"","article_id":"1138905296","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138905296","pubTimestamp":1779277157,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 20, Roivant Sciences rose 8.12% in pre-market trading, trading at $30.02/share, with trading volume of approximately $1.71 million.On the news front, the company reported its fiscal fourth...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ROIV":"Roivant Sciences Ltd."},"translate_title":"动向提示|Roivant Sciences盘前涨8.12%公布第四财季业绩及业务更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":1},"content_text":"On May 20, Roivant Sciences rose 8.12% in pre-market trading, trading at $30.02/share, with trading volume of approximately $1.71 million.On the news front, the company reported its fiscal fourth quarter and full-year financial results for the period ended March 31, alongside a comprehensive business progress update. Fiscal Q4 earnings per share from continuing operations came in at $0.28, while quarterly revenue of $2.52 million missed the consensus estimate of $3.82 million. Despite the revenue shortfall, the concurrent disclosure of business developments received a positive market response, driving the stock higher in pre-market trading.Roivant Sciences is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines in inflammation and immunology. The company operates through its Vant model, building focused subsidiaries across biopharmaceutical businesses and health technology startups. Its pipeline includes VTAMA for psoriasis and atopic dermatitis, batoclimab and IMVT-1402 targeting autoimmune indications, and RVT-3101 for ulcerative colitis and Crohn's disease.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}